Pancreatic Carcinoma; Lipoprotein a; Overall Survival; Prognosis
Conditions
Keywords
Pancreatic carcinoma; Lipoprotein a; Overall survival; Prognosis
Brief summary
Background: This study aims to assess the prognostic significance of serum lipoprotein (a) \[Lp (a)\] levels on overall survival (OS) and progression free survival (PFS) in individuals diagnosed with pancreatic cancer through the utilization of propensity score matching (PSM). Methods: A retrospective analysis was conducted on the clinicopathological data of 364 patients diagnosed with pancreatic cancer at the Affiliated Hospital of Qingdao University from January 2019 to December 2022. The cut-off value for Lp (a) was determined based on one-year survival rates after diagnosis. Patients were then categorized into the high and low Lp (a) groups. We applied PSM analysis to minimize selection bias. The study compared OS and PFS between two groups by Kaplan-Meier method and analyzed differences using the log-rank test. Additionally, univariate and multivariate Cox-regression analyses were performed to identify prognostic factors among patients.
Interventions
OTHERLp(a)
The cut-off value for Lp (a) was determined based on one-year survival rates after diagnosis. Patients were then categorized into the high and low Lp (a) groups.
Sponsors
jingxue
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients aged over 18 years; (2) Patients with histologically confirmed pancreatic cancer through surgical or puncture procedures; (3) Complete lipid profiles available within one week prior to diagnosis.
Exclusion criteria
* (1) Presence of concurrent malignancies; (2) History of previous treatments such as pancreatectomy, chemotherapy, or radiation therapy; (3) Incomplete clinicopathological information.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| OS | 1-30months | The primary endpoint was overall survival (OS), defined as the time from pathological diagnosis to either death or the most recent follow-up. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS | 1-10months | The secondary measure was the duration from the initial diagnosis to disease progression, referred to as progression-free survival (PFS). Both are measured in months. |
Countries
China
Contacts
Primary ContactJinyue liu
Outcome results
None listed